Table 2.
CRISPR spacer groups shared between subjects and sites
| Percent shared within subject or sample typea | Percent shared for comparisons of different subjects or sample typesa | P valueb | |
|---|---|---|---|
|
SGI CRISPRs |
|
|
|
|
By subject |
|
|
|
| Subject 1 |
96.74 ± 0.63 |
50.20 ± 22.18 |
0.0011 |
| Subject 2 |
94.95 ± 0.73 |
50.00 ± 22.22 |
0.0122 |
| Subject 3 |
96.51 ± 0.50 |
50.07 ± 22.24 |
0.0015 |
| Subject 4 |
71.68 ± 4.22 |
50.23 ± 22.28 |
0.2256 |
|
By sample type |
|
|
|
| Saliva |
14.12 ± 3.64 |
23.93 ± 5.27 |
0.9541 |
| Plaque |
21.35 ± 3.89 |
15.77 ± 4.58 |
0.4491 |
|
SGII CRISPRs |
|
|
|
|
By subject |
|
|
|
| Subject 1 |
95.79 ± 0.70 |
60.90 ± 19.27 |
0.0064 |
| Subject 2 |
99.48 ± 0.06 |
60.94 ± 19.20 |
0.0014 |
| Subject 3 |
95.80 ± 0.56 |
60.67 ± 19.26 |
0.0065 |
| Subject 4 |
89.16 ± 1.76 |
60.85 ± 19.23 |
0.0495 |
|
By sample type |
|
|
|
| Saliva |
15.84 ± 3.40 |
32.88 ± 4.26 |
0.9998 |
| Plaque | 25.64 ± 2.88 | 20.66 ± 3.44 | 0.4869 |
aBased on the mean of 10,000 iterations. 1,000 random spacers were sampled per iteration.
bEmpirical p-value based on the fraction of times the estimated percentage of shared spacer groups for each subject or sample type exceeds that for different subjects or sample types. P-values ≤0.05 are highlighted in bold.